Study summary
A second RAS drug added strong responses on top of daraxonrasib
50%tumors shrank after 2 prior lines of treatment
What was tested
Zoldonrasib, a pill that blocks the specific G12D form of mutated RAS, combined with daraxonrasib, or with chemotherapy, for metastatic pancreatic cancer already treated with other drugs.
What they found
- Tumors shrank in 50% of people after 2 prior lines of treatment and 47% after 3 or more, with disease control in 97% and 90%.
- Added to chemotherapy as a first treatment, 82% of tumors shrank, higher than typical rates for chemotherapy alone.
- A third of people had a serious side effect; one bowel perforation was linked to treatment.
What it means
Early and uncontrolled, but among the strongest response rates reported in pancreatic cancer; now moving into randomized phase 3 trials.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.